gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Gynecologic Cancer

Meeting Abstract (OP337)

Financal calculation of a certified breast center – is there a the benefit?

Beckmann MW, Wagner S, Lux MP, Fasching PA, Universitätsbrustzentrum Franken
[Full Text]
Meeting Abstract (OP338)

Improvement of prognosis of invasive ovarian cancer since 1988, especially in patients younger than 65 years of age: results of the Munich Cancer Registry

Hölscher G, Engel J, Hölzel D
[Full Text]
Meeting Abstract (OP339)

Phase II trial of Docetaxel and Carboplatinum in recurrent platinum sensitive ovarian, peritoneal and tubal cancer - final results

Strauß HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Kölbl H
[Full Text]
Meeting Abstract (OP340)

A randomized multicenter Phase II study on neoadjuvant chemotherapy with Carboplatin and Docetaxel in advanced ovarian carcinomas (PRIMOVAR)

Park TW, Jänicke F, Ortmann O, Hilfrich J, Breitbach GP, Höss C, Möbus V, Dietrich K, Thomssen C, Kuhn W
[Full Text]
Meeting Abstract (OP341)

Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Belau AK, Huober J, Heilmann V, Mueller HH, Burges A, Pfisterer J, Gropp M, Schröder W, Wimberger P, du Bois A
[Full Text]
Meeting Abstract (OP342)

First-line treatment of ovarian cancer FIGO stage IIB–IV using Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP): mature results of a gynecologic cancer intergroup phase III trial of the ago ovar and gineco

Jackisch C, Jackisch C, Pujade-Lauraine E, Olbricht S, Moebus V, Quaas J, Schade-Brittinger C, Richter B, Schroeder W, Lueck HJ, Pfisterer J
[Full Text]
Meeting Abstract (OP343)

Prognostic significance of antibodies to HPV-16 – L1 Virus Like Partikels (VLP) in the sera of patients with invasive cervical cancer

Ackermann S, Mehlhorn G, Fasching PA, Skiba D, Beckmann MW
[Full Text]
Meeting Abstract (OP344)

Expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with disease outcome

Gabriel B, zur Hausen A, Stickeler E, Dietz C, Gitsch G, Fischer DC, Bouda J, Tempfer C, Hasenburg A
[Full Text]
Meeting Abstract (OP345)

Tspan-1 is strongly expressed by ovarian cancer cells

Deißler H, Scholz CJ, Sauer G, Koppold B, Kurzeder C, Kreienberg R, Deissler H
[Full Text]
Meeting Abstract (OP346)

Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.

Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis EP, Schmitt M
[Full Text]
Meeting Abstract (OP347)

Frequently Altered Expression of Wnt Antagonists DKK Family in Ovarian Cancer

An H, Schröter C, Bieker M, Rose F, Gross M, Niederacher D, Engenhart-Cabillic R, An H
[Full Text]
Meeting Abstract (PO348)

Finaly analyzes of biweekly schedule of pegylated liposomal doxorubicin (PLD) in 64 heavily pretreated patients with relapsed ovarian cancer (ROC)

Sehouli J, Oskay-Oezcelik G, Kuehne J, Huindenburg H, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W
[Full Text]
Meeting Abstract (PO349)

Combination therapy with pegliposomal doxorubicin and carboplatin in malignant gynecologic tumours. A prospective multicenter phase-II trial of the AGO-OVAR and the AGO Kommission Uterus

Harter P, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Koelbl H, du Bois A
[Full Text]
Meeting Abstract (PO350)

The Human Endogenous Retroviral gene Syncytin is induced in endometrial Hyperplasia by Tamoxifen via the Estrogen Receptor Pathway

Strick R, Ackermann S, Beckmann MW, Strissel PL
[Full Text]
Meeting Abstract (PO351)

Phase II-Studie mit wöchentlich Docetaxel in Patientinnen mit fortgeschrittenem Endometriumkarzinom, AGO Uterus-4

Günthert A, Ackermann S, Kiesel L, Steiner E, Schröder W, Camara O, Mallmann P, Emons G
[Full Text]
Meeting Abstract (PO352)

Caelyx 20 mg/m2 q2wks in platinum-refractory or early recurrent ovarian or peritoneal cancer - results from a phase II study

Persing M, Beau U, Kendzierski N, Karbe I, Strauss HG, Thomssen C
[Full Text]
Meeting Abstract (PO353)

Expression of glycodelin in human ovarian cancer: immunohistochemistry and possible function

Jeschke U, Kunert-Keil C, Stahn R, Scholz C, Schumacher L, Janni W, Mylonas I, Schröder E, Kuhn C, Mayr D, Briese V, Friese K
[Full Text]
Meeting Abstract (PO354)

Clinical relevance of selected biochemical parameter within amniotic fluid as markers of the disordered pregnancy and under special consideration of Zytokines and Tumormarkers

Albrecht S, Köhler S, Büttner R, Zimmermann T, Kamin G, Albrecht S, Distler W
[Full Text]
Meeting Abstract (PO355)

Expression of inhibin/activin subunits (alpha, betaA and betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers

Worbs S, Shabani N, Mayr D, Dian D, Kuhn C, Jeschke U, Friese K, Mylonas I
[Full Text]
Meeting Abstract (PO356)

A multicenter NOGGO-feasibility study of neoadjuvant concomitant radio-chemotherapy with curative intention in locally advanced cervical carcinoma

Köhler G, Belau A, Nehmzow M, Bartz K, Breitsprecher R
[Full Text]
Meeting Abstract (PO357)

Polymorphism of IL-1 α, IL-1 β and IL-10 in patients with advanced ovarian cancer

Braicu EI, Pirvulescu C, Mustea A, Könsgen D, Sehouli J, Lichtenegger W
[Full Text]
Meeting Abstract (PO358)

Prognostic Role of Expression of IL-1 a, IL-1 b, IL-1 Ra and IL-10 in Advanced Epithelial Ovarian Cancer (OC)

Pirvulescu C, Braicu EI, Mustea A, Könsgen D, Sehouli J
[Full Text]
Meeting Abstract (PO359)

Prognostic impact of micrometasases in pelvic lymph nodes in patients with carcinoma of the cervix uteri

Horn LC, Peter D, Hentschel B, Bilek K
[Full Text]
Meeting Abstract (PO360)

Prognostic significance of inhibin/activin subunits (alpha, betaA and betaB) in human endometrial carcinoma: an immunohistochemical analysis of 294 cases

Mylonas I, Worbs S, Shabani N, Darius D, Mayr D, Kuhn C, Schulze S, Kunze S, Sommer H, Jeschke U, Friese K
[Full Text]
Meeting Abstract (PO361)

Localisation and prediction of lymph node metastases in ovarian cancer

Harter P, Gnauert K, Neugebauer B, Hils R, Buhrmann C, Traut A, Fisseler-Eckhoff A, du Bois A
[Full Text]
Meeting Abstract (PO362)

Implementation of an interdisciplinary Online Tumor Conference as a new tool in the management of gynaecological cancers.

Chekerov R, Sehouli J, Schönerstedt-Zastrau K, Chekerov R, Böhmer D, Denkert C, Wieding A, Heinrich G, Ruhnke M, Lorsbach M, Lichtenegger W
[Full Text]
Meeting Abstract (PO363)

HPV- infection in HIV-infected women as a tumor marker of recurrent cervical dyplasia

Gingelmaier A, Grubert T, Kästner R, Mylonas I, Weissenbacher T, Barthell E, Bergauer F, Friese K
[Full Text]
Meeting Abstract (PO364)

Expression of HPV, steroid receptors and inhibin/activin subunits in diverse parts of endometroid adenocarcinoma with squamous differentiation

Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K
[Full Text]
Meeting Abstract (PO365)

Proliferation and Cell-Cell Fusion of Endometrial Carcinoma are induced by the Human Endogenous Retroviral Syncytin and regulated by TGF-β

Strick R, Ackermann S, Langbein M, Beckmann MW, Strissel PL
[Full Text]
Meeting Abstract (PO366)

The results of a prospective study from expression of VEGF, VEGF-C, VEGF-D in patients with ovarian cancer

Sentschuk- Schmidt N, Mustea A, Koensgen D, Sehouli J, Lichtenegger W
[Full Text]
Meeting Abstract (PO367)

Nutritional status of outpatients with gynaecologic cancer

Hollatz E, Kuhberg M, Loschen K, Sehouli J, Lichtenegger W
[Full Text]
Meeting Abstract (PE368)

Management and course of histological verified cervical carcinoma in situ during pregnancy

Ackermann S, Mehlhorn G, Reissmann C, Beckmann MW
[Full Text]
Meeting Abstract (PE369)

Feasibility and outcome of primary and adjuvant cervical cancer patients treatment with simultaneous Radio-Chemotherapy in an outpatient setting

Buhrmann C, Hils R, Prott FJ, Gnauert K, Traut A, du Bois A
[Full Text]
Meeting Abstract (PE370)

Advanced Ovarian Cancer (OC) with Mainly Extraovarian Manifestation in a 22-Year Old Pregnant Patient: Diagnostic Issues

Belau AK, Bartz K, Hinken B, Schwesinger G, Koehler G
[Full Text]
Meeting Abstract (PE371)

Prognostic impact of hemoglobin levels before and throughout a carboplatin/taxane-based chemotherapy on patients with primary epithelial ovarian cancer

Eichbaum M, Weiss L, Bruckner T, Gebauer G, Schneeweiss A, Fersis N, Sohn C
[Full Text]
Meeting Abstract (PE372)

Ovarian Cancer Treatment Reality in Northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as the cause for inferior survival. A Retrospective Study of 139 Patients Receiving Chemotherapy and Palliative Care in an Oncology Group Practice.

Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H
[Full Text]
Meeting Abstract (PE373)

Detection ofGene Amplification in Dysplastic Lesion of the Vulva and Cervix by FISH Analysis of Chromosome 3 - preliminary results

Gebauer G, Schleibaum J, Aulmann S, Sohn C, Sinn HP
[Full Text]
Meeting Abstract (PE374)

Radiochemosensitivity testing (TRCA) in Gynecological Cancers

Albrecht S, Franz R, Zimmermann T, Doerfler A, Gatzweiler A, Distler W
[Full Text]
Meeting Abstract (PE375)

Long term results of postoperative radiotherapy in carcinoma of the uterine cervix

Schüller P, Funk WK, Willich N
[Full Text]